ライフサイエンスコーパス: renal transplantation

1 -stage CKD (defined as long-term dialysis or renal transplantation).

2 acute kidney injury requiring dialysis; and renal transplantation).

3 main higher with chronic dialysis than after renal transplantation.

4 ts rejection with high sensitivity after non-renal transplantation.

5 ificant prognostic implications in pediatric renal transplantation.

6 tudy was to determine barriers to preemptive renal transplantation.

7 on, remain a major source of morbidity after renal transplantation.

8 s cancer have increasingly been accepted for renal transplantation.

9 n changes in the left ventricular mass after renal transplantation.

10 contributor to delayed graft function after renal transplantation.

11 on led to compelling success for outcomes of renal transplantation.

12 termined as the need for chronic dialysis or renal transplantation.

13 n changes in the left ventricular mass after renal transplantation.

14 ost common urological complication following renal transplantation.

15 o cases of AMR resistant to eculizumab after renal transplantation.

16 splantation and is especially feasible after renal transplantation.

17 year and after a follow-up of 3 years after renal transplantation.

18 P-2 deficiency in an isogenic mouse model of renal transplantation.

19 f anemia on patient and graft survival after renal transplantation.

20 and highly sensitized recipients undergoing renal transplantation.

21 educe IRI and improve organ preservation for renal transplantation.

22 f an intermediate period of EVNP in clinical renal transplantation.

23 on dialysis but improves significantly after renal transplantation.

24 are essential immunosuppressive drugs after renal transplantation.

25 tezomib to reduce anti-HLA antibodies before renal transplantation.

26 associated with donor-specific tolerance for renal transplantation.

27 ients who were desensitized for incompatible renal transplantation.

28 monitoring and detection of thrombosis after renal transplantation.

29 raft function (DGF) and graft survival after renal transplantation.

30 n pediatric patients undergoing living-donor renal transplantation.

31 sk stratifying patients being considered for renal transplantation.

32 outcomes following HLA antibody incompatible renal transplantation.

33 low-grade proteinuria or microalbuminuria in renal transplantation.

34 We report two cases of PLS occurring after renal transplantation.

35 over the followup period, with 10 undergoing renal transplantation.

36 s (EVR) has demonstrated good efficacy after renal transplantation.

37 ctor for successful treatment outcomes after renal transplantation.

38 be exploited to improve clinical outcomes in renal transplantation.

39 he concept in clinical settings of islet and renal transplantation.

40 tric patients during the first 2 years after renal transplantation.

41 trial of tolerance in HLA-identical sibling renal transplantation.

42 lation blocking agent CTLA4Ig, 7 days before renal transplantation.

43 patients who underwent primary living-donor renal transplantation.

44 ed by the immunosuppressive regimens used in renal transplantation.

45 or exposure during the first 6 months after renal transplantation.

46 lysis patients should not deter referral for renal transplantation.

47 erolimus-based treatment regimens in de novo renal transplantation.

48 motes graft function in an isograft model of renal transplantation.

49 ce or prevent CNI-induced hypertension after renal transplantation.

50 RD and severe systolic dysfunction underwent renal transplantation.

51 preserve renal function in animal models of renal transplantation.

52 uminex beads in male patients awaiting first renal transplantation.

53 tibia decrease over a 6-month interval after renal transplantation.

54 sents a major obstacle for patients awaiting renal transplantation.

55 polymorphisms on SRL-induced dyslipidemia in renal transplantation.

56 l utility for invasive fungal diseases after renal transplantation.

57 el thrombosis is a severe complication after renal transplantation.

58 and effective immunosuppressive regimen for renal transplantation.

59 e useful in therapeutic monitoring of SRL in renal transplantation.

60 rcome incompatibility barriers in live-donor renal transplantation.

61 ho may not otherwise have the opportunity of renal transplantation.

62 sibility of allograft rejection in pediatric renal transplantation.

63 vidence of transmission of S. stercoralis by renal transplantation.

64 tients for SF immunosuppression in pediatric renal transplantation.

65 ich could eventually lead to applications in renal transplantation.

66 leting agent, is well tolerated in pediatric renal transplantation.

67 ple aortic aneurysms, respectively underwent renal transplantation.

68 omorbidity still had a survival benefit from renal transplantation.

69 cause of renal graft loss after living-donor renal transplantation.

70 ns of memory CD4 T cells in a mouse model of renal transplantation.

71 nts are the fastest-growing group in need of renal transplantation.

72 ney function, and this effect is reversed by renal transplantation.

73 the recent periods of increasing success in renal transplantation.

74 policy implications for maximizing value in renal transplantation.

75 d risk of rejection in the early phase after renal transplantation.

76 specificity for the diagnosis of TCMVR after renal transplantation.

77 not be an absolute contraindication against renal transplantation.

78 e transplantation waiting list who underwent renal transplantation.

79 rogressed to ESRD and subsequently underwent renal transplantation.

80 most common cause of early graft loss after renal transplantation.

81 second primary cancers are infrequent after renal transplantation.

82 rs limiting long-term outcome in cardiac and renal transplantation.

83 e risk factors for primary CMV disease after renal transplantation.

84 arkers, with a specific focus on progress in renal transplantation.

85 properties of HDL remain dysfunctional after renal transplantation.

86 oncentration achievement of tacrolimus after renal transplantation.

87 ediated rejection is a major complication in renal transplantation.

88 ntal effect on early clinical outcomes after renal transplantation.

89 e to support an absolute upper age limit for renal transplantation?

90 During the first year after renal transplantation, 14 patients developed severe infe

91 2012 in the Assessment of Acute Rejection in Renal Transplantation (AART) study.

92 impacts racial disparities in deceased donor renal transplantation access has not been examined in th

93 In renal transplantation, acute rejection (AR) increases th

94 We identified 480 consecutive cases of renal transplantation after hand-assisted laparoscopic l

95 ney allocation variance to allow for delayed renal transplantation after liver transplantation may pr

96 One solution is to perform live-donor renal transplantation after the depletion of donor-speci

97 Among 480 renal transplantations after living donor nephrectomy, u

98 ne samples from 221 individuals 1 year after renal transplantation (age 52 +/- 13 years, 55% male, 93

99 expanded mesenchymal stromal cells tested in renal transplantation, AKI, and CKD.

100 asses are at an increased risk for DGF after renal transplantation, although differences in non-death

101 objective was to determine BIPA's impact on renal transplantation among elderly patients (age >/=65

102 The utility of renal transplantation among individuals with two prior r

103 diovascular), with 655 patients censored for renal transplantation and 1183 for loss to follow-up.

104 tients undergoing antibody-incompatible (Ai) renal transplantation and 319 antibody-compatible transp

105 Dyslipidemia is a common finding after renal transplantation and a significant risk factor in t

106 -seropositive, recipient-seropositive (D+R+) renal transplantation and examined recipients' CMV antig

107 lyzed our institution's experience with HCV+ renal transplantation and factors contributing to subseq

108 luid from DCD (donation after cardiac death) renal transplantation and four isolates in the recipient

109 virus-6 (HHV-6) is known to reactivate after renal transplantation and has been associated with sever

110 hether antibodies to vimentin are made after renal transplantation and if production is associated wi

111 gh expression of WISE mRNA in a rat model of renal transplantation and in kidneys from normal rats.

112 Active HHV-6 infection occurs early after renal transplantation and is mostly asymptomatic.

113 chemia-reperfusion injury, pigs subjected to renal transplantation and liver transplantation patients

114 ed urinary protein excretion is common after renal transplantation and portends worse outcome.

115 scribe the frequency of return to work after renal transplantation and related characteristics.

116 l was used to analyze the chance of having a renal transplantation and the effect of transplantation

117 ous ureteroplasty of ureteric stenosis after renal transplantation and to compare the outcomes to tho

118 ial cause of humoral alloimmune responses in renal transplantation, and de novo donor-specific anti-h

119 mprovement of long-term graft survival after renal transplantation, and have potentially unlimited ap

120 oprine, a drug to prevent acute rejection in renal transplantation, and kaempferol and esculetin, two

121 toxicity from clinical studies of islet and renal transplantation, and of rapamycin as an anticancer

122 onal antibody) has been primarily studied in renal transplantation, and the experience of alemtuzumab

123 sion injury (IRI) remains a major problem in renal transplantation, and the inflammatory response to

124 clinically indicated as a CNI alternative in renal transplantation, and we have endeavored to develop

125 role of renin-angiotensin system blockade in renal transplantation are inconclusive.

126 graft outcomes in patients undergoing repeat renal transplantation are inferior compared to first-tim

127 graft outcomes in patients undergoing repeat renal transplantation are inferior compared to first-tim

128 nogenesis of urothelial carcinoma (UC) after renal transplantation are lacking.

129 sparities in clinical outcomes after de novo renal transplantation are well documented; whether the e

130 reatinine] x 1000, mg/mM) 1 year after first renal transplantation as predictors of transplant failur

131 etaphysis was performed within 2 weeks after renal transplantation (baseline) and 6 months later in 4

132 o determine the clinical relevance of T50 in renal transplantation, baseline serum T50 was measured i

133 Data of 1023 women, who underwent a renal transplantation between 1968 and 2008, were collec

134 In 46 pediatric patients who underwent renal transplantation between 2002 and 2003, the variati

135 tel Children's Hospital, UCLA, who underwent renal transplantation between January 2003 and October 2

136 an incident cohort of patients who underwent renal transplantation between June 2004 and September 20

137 lence and sequelae of EBV infection in adult renal transplantation beyond the first year.

138 To lessen barriers and facilitate renal transplantation, black men and women, white women,

139 et to be studied in late TID or in pediatric renal transplantation; both questions were investigated.

140 on increases the risk of complications after renal transplantation, but the mechanisms controlling do

141 genesis of specific disease conditions after renal transplantation, but their utility as a biomarker

142 Delayed graft function (DGF) after renal transplantation can be diagnosed according to seve

143 (c) A renal transplantation can be performed in the absence of

144 Renal transplantation can be performed safely in childre

145 Reactivation of polyomavirus BK (BKV) after renal transplantation can lead to allograft dysfunction

146 esistive index is routinely measured in many renal-transplantation centers for assessment of renal-al

147 n safety and efficacy of early (week 7 after renal transplantation) conversion from cyclosporine A (C

148 onic hepatitis C virus prohibiting cadaveric renal transplantation (CRT).

149 derwent bilateral nephrectomy and orthotopic renal transplantation (day 0).

150 n of chemokines and their receptors in human renal transplantation defines associations between chemo

151 This first series of EVNP in renal transplantation demonstrates that this technique i

152 Outcome after renal transplantation depends on patient compliance and

153 Within 4 weeks of renal transplantation, deteriorating graft function and

154 In the clinical settings of islet and renal transplantation, donor exosomes with respective ti

155 In the setting of renal transplantation, eculizumab has so far proved effe

156 Racial disparities in access to renal transplantation exist, but the effects of race and

157 Renal transplantation experiments confirmed that extrare

158 To measure the risk of cancer in renal transplantation for recipients who had previously

159 etrospective review of patients assessed for renal transplantation from 2000 to 2009.

160 rk for Organ Sharing) data on deceased donor renal transplantation from 2000 to 2010.

161 e 90 CMV-negative patients receiving a first renal transplantation from a CMV-positive donor in this

162 xperienced allograft dysfunction following a renal transplantation from a donation after cardiac deat

163 A retrospective review of the outcome of renal transplantation from pediatric donor (<18 years) k

164 t-beating donors were allowed to perform 236 renal transplantations from September 2005 to December 2

165 Renal transplantation (from the same BMT donor) was perf

166 HLA antibody-incompatible renal transplantation had a high success rate if the CDC

167 Renal transplantation has become the preferred treatment

168 eukocyte antigen (HLA) antibody-incompatible renal transplantation has been increasingly performed si

169 Urinary dd-cfDNA after renal transplantation has patient specific thresholds, r

170 Renal transplantation has transformed the life of patien

171 Short-term outcomes in renal transplantation have improved significantly in the

172 socioeconomic status (SES) on early steps of renal transplantation have not been well explored.

173 ely derived from the early Banff meetings on renal transplantation, have somewhat arbitrarily been ap

174 ctomy can be safely performed at the time of renal transplantation, however, carries a significantly

175 e rejection risk during the first year after renal transplantation.Impaired glucose tolerance was not

176 vated parathyroid hormone (PTH) level, after renal transplantation in a contemporary cohort.

177 -107 may help to better identify TCMVR after renal transplantation in a precise and clinically applic

178 potential benefit in patients with IGT after renal transplantation in addition to lifestyle modificat

179 Data on the outcome of renal transplantation in antineutrophil cytoplasmic anti

180 We performed renal transplantation in mice to model CAD and identifie

181 The benefit of renal transplantation in obese patients is controversial

182 al Data System registry to analyze trends in renal transplantation in patients with human immunodefic

183 erly have benefited from increased access to renal transplantation in recent years.

184 ribed after clinical ABO-incompatible (ABOi) renal transplantation in the 1980s and is recognized as

185 A total of 103 (24%) patients needed a renal transplantation in the LIST group with 16 (4%) rec

186 However, the feasibility of renal transplantation in the setting of cardiac dysfunct

187 The waiting time for deceased donor renal transplantation in the United States continues to

188 Racial disparities persist in access to renal transplantation in the United States, but the degr

189 iated with the development of diabetes after renal transplantation included older recipient age, fema

190 onor-specific antibody-secreting cells after renal transplantation indicates that B cells respond spe

191 jection may exist as early as 3 months after renal transplantation indicates that optimal management

192 emtuzumab as induction immunosuppression for renal transplantation introduces the possibility of long

193 Renal transplantation is a lifesaving intervention for e

194 icosteroid withdrawal/avoidance in pediatric renal transplantation is associated with a significant i

195 Renal transplantation is associated with reduction in th

196 alence of left ventricular hypertrophy after renal transplantation is blunted by high sodium intake.

197 Neutropenia after renal transplantation is common and is associated with a

198 ion in the prognosis of patients who undergo renal transplantation is controversial.

199 suppressive regimen in benefit-risk ratio in renal transplantation is debated.

200 al premalignancies over a period of 40 years renal transplantation is presented.

201 rATG induction in living donor renal transplantation is safe and associated with a low

202 Renal transplantation is the optimum treatment for end-s

203 Renal transplantation is the preferred treatment for pat

204 Renal transplantation is the renal replacement modality

205 Renal transplantation is the treatment of choice for end

206 challenge of immunosuppression in pediatric renal transplantation is to balance preventing rejection

207 of human leukocyte antigen (HLA) matching in renal transplantation is well recognized, with HLA-DR co

208 eperfusion injury (IRI), an obligate part of renal transplantation, is not yet well understood.

209 Early after renal transplantation, it is often challenging to achiev

210 rm effects of mycophenolate mofetil (MMF) in renal transplantation, its introduction at different tim

211 eresis-based strategies with some success in renal transplantation, kidney paired donation (KPD) is a

212 We present our experience of living-donor renal transplantation (LDRT) using pretransplant stem ce

213 nce induction and sustenance in living donor renal transplantation (LDRT).

214 ciated with severe acute rejection following renal transplantation, leading us to investigate whether

215 Renal transplantation loss occurred in one patient who d

216 donor positive/recipient negative allogeneic renal transplantation model by flow cytometry and immuno

217 We used a syngeneic rat renal transplantation model of IRI with bilaterally neph

218 In a murine CMV (MCMV) renal transplantation model, ganciclovir prophylaxis imp

219 lated in the glomeruli and arteries in a rat renal transplantation model.

220 Renal transplantation must increasingly serve a populati

221 nts after heart transplantation (HTx, n=57), renal transplantation (n=1), or hematopoietic stem cell

222 he number of patients who could benefit from renal transplantation new strategies need to be consider

223 observed within minutes after reperfusion in renal transplantation of recipients with FSGS that will

224 ia is a feature of CKD and a complication of renal transplantation, often caused by impaired producti

225 or parathyroidectomy to define the impact of renal transplantation on circulating sclerostin levels a

226 dysfunction and in particular the effects of renal transplantation on markers of endothelial function

227 ing of cardiac dysfunction and the effect of renal transplantation on this progression remain poorly

228 The impact of renal transplantation on trabecular and cortical bone mi

229 The influence of DSA-SPA on repeat renal transplantation outcomes has not been previously s

230 The influence of DSA-SPA on repeat renal transplantation outcomes has not been previously s

231 The demand for renal transplantation outweighs the availability of orga

232 increased incidence of new-onset diabetes in renal transplantation patients over those receiving rapa

233 Renal transplantation patients requiring valve replaceme

234 n and calibration in the Patient Outcomes in Renal Transplantation (PORT) study cohort.

235 ignificantly reduce the odds for NODAT after renal transplantation, presumably via insulin-mediated p

236 In vivo, after orthotopic RENCA cell renal transplantation, pulmonary tumor spread was inhibi

237 India with a population of 1.2 billion has a renal transplantation rate of 3.25 per million populatio

238 vestigated the determinants of depression in renal transplantation recipients (RTRs) and the associat

239 Prophylactic ureteric stenting in renal transplantation reduces major urological complicat

240 The principle barrier to renal transplantation referral before dialysis was patie

241 Infection after renal transplantation remains a major cause of morbidity

242 Renal transplantation remains contentious in patients wi

243 Renal transplantation remains the best treatment option

244 or the treatment of rheumatoid arthritis and renal transplantation, respectively.

245 muM] for healthy controls; P<0.001); whereas renal transplantation resulted in substantial reductions

246 During the last 20 years, waiting lists for renal transplantation (RT) have grown significantly olde

247 he association of anemia with outcomes after renal transplantation (RT) is unclear.

248 iogenic factors on endothelial repair during renal transplantation (RT)-related ischemia-reperfusion.

249 dicts lower patient and graft survival after renal transplantation (RT).

250 S during in vivo cold storage and subsequent renal transplantation (RTx) and in vitro cold hypoxic re

251 , and fertility in adult male patients after renal transplantation (RTx) during childhood or adolesce

252 mothers after liver transplantation (LTx) or renal transplantation (RTx) with the assessment of certa

253 of CMV-related complications in the de novo renal transplantation setting.

254 to reduce the high rate of AKI in the human renal transplantation setting.

255 We propose that the diagnosis of CRS after renal transplantation should be based on the following t

256 s after SLKT, our data strongly suggest that renal transplantation should be deferred in liver recipi

257 mpact significantly on CIT in deceased donor renal transplantation, some of which are modifiable; att

258 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study was a double-blind randomize

259 The Heme Oxygenase-1 in renal Transplantation study was a randomized, placebo-co

260 e placebo arm of the Assessment of Lescol in Renal Transplantation study, a randomized controlled tri

261 s a substudy of the Certican Nordic Trial in Renal Transplantation study, a randomized controlled tri

262 placebo group of the Assessment of Lescol in Renal Transplantation study.

263 rom this trial of tolerance in HLA-identical renal transplantation suggest that predictive genomic bi

264 urgeon versus urologist; history of previous renal transplantations; technique of ureteral anastomosi

265 times higher in patients on dialysis or post-renal transplantation than in the general population.

266 will return to insulin therapy after repeat renal transplantation, the relatively high frequency of

267 In renal transplantation, the use of immunoglobulin (Ig) cy

268 patient quality of care including access to renal transplantation therapy (RTT).

269 After renal transplantation, there is very high risk of diseas

270 donors has allowed expansion of living donor renal transplantation to account for one third of all re

271 We devised a model of renal transplantation to elucidate the initial stages of

272 and monitoring before and periodically after renal transplantation to prevent morbidity and mortality

273 nsitized patients who subsequently underwent renal transplantation (treatment group).

274 Using the Assessment of Lescol in Renal Transplantation trial population, a formula for 7-

275 e used data from the Assessment of Lescol in Renal Transplantation trial, which are randomly divided

276 RTR derived from the Assessment of LEscol in Renal Transplantation trial.

277 ibe the case of a 52-year-old man awaiting a renal transplantation, undergoing elective orthopedic su

278 ped Pneumocystis jirovecii infections at the renal transplantation unit of Brest University Hospital

279 been some reports of acceptable outcomes of renal transplantation using kidneys from donors with DIC

280 e effect of gender on access to the national renal transplantation waiting list was assessed in 9497

281 en and 34.1% of the women were placed on the renal transplantation waiting list.

282 of pediatric patients on the deceased-donor renal transplantation waiting list.

283 Gender inequity in access to renal transplantation waiting lists, in favor of men, ha

284 significant mutation in INF2 In this family, renal transplantation was associated with post-transplan

285 Tacrolimus variability 6 to 12 months after renal transplantation was calculated, and outcomes were

286 Renal transplantation was the treatment of choice and ha

287 outbreak of A. baumannii emerging after DCD renal transplantation was tracked to understand the tran

288 on due to decreased dopamine metabolism, and renal transplantation was used to determine whether the

289 s and mycophenolate mofetil (MMF) therapy in renal transplantation, we analyzed the peripheral B- and

290 tacept in patients with recurrent FSGS after renal transplantation, we investigated B7-1 expression i

291 s) from six UK hospitals who were undergoing renal transplantation were recruited and randomly assign

292 ion, the risks for four cancer groups during renal transplantation were significantly increased: anog

293 bruary 2010 and January 2012, a total of 217 renal transplantations were performed from living donors

294 increases the risks of four cancer types in renal transplantation while sparing the others.

295 bilateral nephrectomy and class I-mismatched renal transplantation with a 12-day course of cyclospori

296 sorders (PTLD) are a common malignancy after renal transplantation with a high incidence of PTLD desc

297 vels appear to show a biphasic pattern after renal transplantation with a rapid and profound decrease

298 Renal transplantation with alemtuzumab induction followe

299 on of transcriptional genomic information to renal transplantation, with specific reference to acute

300 In the brown Norway to Lewis rat renal transplantation, xenon administered to donor or re